Next big wave of patent cliffs ahead; biopharmaceutical M&A expected to increase (NYSE:ABBV)
Olivier LeMoal With a significant number of blockbuster drugs at risk of losing market exclusivity in the next five years, ...
Olivier LeMoal With a significant number of blockbuster drugs at risk of losing market exclusivity in the next five years, ...